P139 Dilution studies establish hla donor-specific antibodies as a predictive biomarker for selection of amr treatment in lung transplant recipients.

Highlights from the article: Antibody-mediated rejection (AMR) caused by HLA donor-specific antibodies (DSA) is an important cause of graft failure after lung transplantation. To test whether high level DSAs could be treated with more aggressive protocol, three patients with strong DSA who needed AMR treatment underwent 4 double TPE sessions with bortezomib and IVIG as previously described by Patel et al. for pre-transplant desensitization.